088264552	088264552	CD	B-NP	O
|	|	NN	I-NP	O
SCH	SCH	NN	I-NP	O
|	|	NN	I-NP	O
39713635	39713635	CD	I-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
2984570	2984570	CD	B-NP	O
|	|	CC	I-NP	O
1/9/2006	1/9/2006	CD	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
AM	AM	VBP	B-VP	O
|	|	JJ	B-NP	B-protein
L	L	NNP	I-NP	I-protein
Carotid	Carotid	NNP	I-NP	I-protein
Artery	Artery	NNP	I-NP	I-protein
Stent	Stent	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
DIS	DIS	NNP	I-NP	O
|	|	NNP	I-NP	O
Admission	Admission	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
2/29/2006	2/29/2006	CD	B-NP	O
Report	Report	NNP	I-NP	O
Status	Status	NNP	I-NP	O
:	:	:	O	O
Discharge	Discharge	NNP	B-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
6/4/2006	6/4/2006	CD	B-NP	O
******	******	SYM	I-NP	O
FINAL	FINAL	NN	I-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
ORDERS	ORDERS	NNS	I-NP	O
******	******	SYM	O	O
RENTERIA	RENTERIA	NNP	B-NP	O
,	,	,	O	O
ALBERTO	ALBERTO	NNP	B-NP	O
E.	E.	NNP	I-NP	O
031-08-99-2	031-08-99-2	CD	I-NP	O
Inggoprings	Inggoprings	NNP	I-NP	O
Service	Service	NNP	I-NP	O
:	:	:	O	O
CAR	CAR	NN	B-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
PATIENT	PATIENT	NN	I-NP	O
ON	ON	NN	I-NP	O
:	:	:	O	O
5/18/06	5/18/06	CD	B-NP	O
AT	AT	NN	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
PM	PM	NN	I-NP	O
CONTINGENT	CONTINGENT	NN	I-NP	O
UPON	UPON	NN	I-NP	O
Attending	Attend	VBG	B-VP	O
evaluation	evaluation	NN	B-NP	O
WILL	WILL	NNP	I-NP	O
D/C	D/C	NNP	I-NP	O
ORDER	ORDER	NNP	I-NP	O
BE	BE	NNP	I-NP	O
USED	USED	NNP	I-NP	O
AS	AS	NNP	I-NP	O
THE	THE	NNP	I-NP	O
D/C	D/C	NNP	I-NP	O
SUMMARY	SUMMARY	NNP	I-NP	O
:	:	:	O	O
YES	YES	NNP	B-NP	O
Attending	Attending	NNP	I-NP	O
:	:	:	O	O
BUDESA	BUDESA	NNP	B-NP	O
,	,	,	O	O
JUNIOR	JUNIOR	NNP	B-NP	O
C.	C.	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
CODE	CODE	NNP	I-NP	O
STATUS	STATUS	NNP	I-NP	O
:	:	:	O	O
Full	Full	JJ	B-NP	O
code	code	NN	I-NP	O
DISPOSITION	DISPOSITION	NN	I-NP	O
:	:	:	O	O
Home	Home	NN	B-NP	O
w	w	NN	I-NP	O
/	/	SYM	B-NP	O
services	service	NNS	I-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
MEDICATIONS	MEDICATIONS	NNS	I-NP	O
:	:	:	O	O
PLAVIX	PLAVIX	CD	B-NP	O
-LRB-	-LRB-	NN	I-NP	O
CLOPIDOGREL	CLOPIDOGREL	NN	I-NP	O
-RRB-	-RRB-	HYPH	O	O
75	75	CD	B-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
DAILY	DAILY	NNP	I-NP	O
Instructions	Instruction	NNPS	I-NP	O
:	:	:	O	O
Starting	Starting	NNP	B-NP	O
Today	Today	NNP	I-NP	O
NEORAL	NEORAL	NNP	I-NP	O
CYCLOSPORINE	CYCLOSPORINE	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
CYCLOSPORINE	CYCLOSPORINE	NNP	I-NP	O
MICRO	MICRO	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
NEORAL	NEORAL	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
75	75	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
BID	BID	NNP	I-NP	O
Food/Drug	Food/Drug	NNP	I-NP	O
Interaction	Interaction	NNP	I-NP	O
Instruction	Instruction	NNP	I-NP	O
Avoid	Avoid	NNP	I-NP	O
grapefruit	grapefruit	NN	I-NP	O
unless	unless	IN	B-SBAR	O
MD	MD	NN	B-NP	B-DNA
instructs	instruct	NNS	I-NP	I-DNA
otherwise	otherwise	RB	B-ADVP	O
.	.	.	O	O

Give	Give	VB	B-VP	O
with	with	IN	B-PP	O
meals	meal	NNS	B-NP	O
Override	Override	NNP	I-NP	O
Notice	Notice	NNP	I-NP	O
:	:	:	O	O
Override	Override	NNP	B-NP	O
added	add	VBD	B-VP	O
on	on	IN	B-PP	O
2/12/06	2/12/06	CD	B-NP	O
by	by	IN	B-PP	O
GREGOROFF	GREGOROFF	NN	B-NP	B-protein
,	,	,	O	O
WALLACE	WALLACE	NN	B-NP	O
,	,	,	O	O
M.D.	M.D.	NN	B-NP	O
on	on	IN	B-PP	O
order	order	NN	B-NP	O
for	for	IN	B-PP	O
PRAVACHOL	PRAVACHOL	NN	B-NP	B-protein
PO	PO	NN	I-NP	I-protein
-LRB-	-LRB-	NN	I-NP	I-protein
ref	ref	NN	I-NP	I-protein
#	#	#	B-NP	I-protein
213792596	213792596	CD	I-NP	I-protein
-RRB-	-RRB-	NNP	I-NP	I-protein
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
CYCLOSPORINE	CYCLOSPORINE	NNP	B-NP	O
&	&	CC	I-NP	O
PRAVASTATIN	PRAVASTATIN	NNP	I-NP	O
SODIUM	SODIUM	NNP	I-NP	O
Reason	Reason	NNP	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
md	md	NN	B-NP	B-DNA
aware	aware	JJ	I-NP	I-DNA
COLACE	COLACE	NN	I-NP	I-DNA
-LRB-	-LRB-	NNP	I-NP	I-DNA
DOCUSATE	DOCUSATE	NNP	I-NP	I-DNA
SODIUM	SODIUM	NNP	I-NP	I-DNA
-RRB-	-RRB-	NNP	I-NP	I-DNA
100	100	CD	I-NP	I-DNA
MG	MG	NNP	I-NP	I-DNA
PO	PO	NNP	I-NP	I-DNA
BID	BID	NNP	I-NP	I-DNA
PRN	PRN	NNP	I-NP	I-DNA
Constipation	Constipation	NNP	I-NP	I-DNA
ENTERIC	ENTERIC	NNP	I-NP	I-DNA
COATED	COATED	NNP	I-NP	I-DNA
ASA	ASA	NNP	I-NP	I-DNA
325	325	CD	I-NP	I-DNA
MG	MG	NNP	I-NP	I-DNA
PO	PO	NNP	I-NP	I-DNA
DAILY	DAILY	NNP	I-NP	I-DNA
PEPCID	PEPCID	NNP	I-NP	I-DNA
-LRB-	-LRB-	NNP	I-NP	I-DNA
FAMOTIDINE	FAMOTIDINE	NNP	I-NP	I-DNA
-RRB-	-RRB-	NNP	I-NP	I-DNA
20	20	CD	I-NP	I-DNA
MG	MG	NNP	I-NP	I-DNA
PO	PO	NNP	I-NP	I-DNA
BID	BID	NNP	I-NP	I-DNA
Instructions	Instruction	NNPS	I-NP	I-DNA
:	:	:	O	O
resume	resume	VB	B-VP	O
zantac	zantac	NN	B-NP	B-protein
150mg	150mg	NN	I-NP	I-protein
bid	bid	NN	I-NP	I-protein
at	at	IN	B-PP	I-protein
discharge	discharge	NN	B-NP	I-protein
FERROUS	FERROUS	NNP	I-NP	I-protein
SULFATE	SULFATE	NNP	I-NP	I-protein
325	325	CD	I-NP	I-protein
MG	MG	NNP	I-NP	I-protein
PO	PO	NNP	I-NP	I-protein
TID	TID	NNP	I-NP	I-protein
Food/Drug	Food/Drug	NNP	I-NP	I-protein
Interaction	Interaction	NNP	I-NP	I-protein
Instruction	Instruction	NNP	I-NP	I-protein
Avoid	Avoid	NNP	I-NP	I-protein
milk	milk	NN	I-NP	I-protein
and	and	CC	I-NP	O
antacid	antacid	NN	I-NP	B-protein
FUROSEMIDE	FUROSEMIDE	NNP	B-NP	I-protein
40	40	CD	I-NP	I-protein
MG	MG	NNP	I-NP	I-protein
PO	PO	NNP	I-NP	I-protein
DAILY	DAILY	NNP	I-NP	I-protein
GLYBURIDE	GLYBURIDE	NNP	I-NP	I-protein
10	10	CD	I-NP	I-protein
MG	MG	NNP	I-NP	I-protein
PO	PO	NNP	I-NP	I-protein
QAM	QAM	NNP	I-NP	I-protein
LANTUS	LANTUS	NNP	I-NP	I-protein
-LRB-	-LRB-	NNP	I-NP	I-protein
INSULIN	INSULIN	NNP	I-NP	I-protein
GLARGINE	GLARGINE	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
20	20	CD	I-NP	O
UNITS	UNITS	NNP	I-NP	O
SC	SC	NNP	I-NP	O
QAM	QAM	NNP	I-NP	O
Starting	Starting	NNP	I-NP	O
IN	IN	NNP	I-NP	O
AM	AM	VBP	B-VP	O
on	on	IN	B-PP	O
5/13	5/13	CD	B-NP	O
TOPROL	TOPROL	NN	I-NP	O
XL	XL	NN	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
METOPROLOL	METOPROLOL	NNP	I-NP	O
SUCCINATE	SUCCINATE	NNP	I-NP	O
EXTENDED	EXTENDED	NNP	I-NP	O
RELEASE	RELEASE	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
50	50	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
DAILY	DAILY	NNP	I-NP	O
HOLD	HOLD	NN	I-NP	O
IF	IF	NN	I-NP	O
:	:	:	O	O
SBP	SBP	NN	B-NP	B-protein
<	<	SYM	O	O
100	100	CD	B-NP	O
,	,	,	O	O
HR	HR	NN	B-NP	O
<	<	SYM	O	O
55	55	CD	B-NP	O
Food/Drug	Food/Drug	NNP	I-NP	O
Interaction	Interaction	NNP	I-NP	O
Instruction	Instruction	NNP	I-NP	O
Take	Take	NNP	I-NP	O
consistently	consistently	RB	B-ADVP	O
with	with	IN	B-PP	O
meals	meal	NNS	B-NP	O
or	or	CC	B-PP	O
on	on	IN	B-PP	O
empty	empty	JJ	B-NP	O
stomach	stomach	NN	I-NP	O
.	.	.	O	O

Number	Number	NN	B-NP	O
of	of	IN	B-PP	O
Doses	Dose	NNS	B-NP	O
Required	Require	VBN	B-VP	O
-LRB-	-LRB-	HYPH	B-NP	O
approximate	approximate	JJ	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
:	:	:	O	O
2	2	CD	B-NP	O
CELLCEPT	CELLCEPT	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
MYCOPHENOLATE	MYCOPHENOLATE	NN	I-NP	O
MOFETIL	MOFETIL	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
1	1	CD	I-NP	O
,	,	,	I-NP	O
000	000	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
BID	BID	NNP	I-NP	O
Food/Drug	Food/Drug	NNP	I-NP	O
Interaction	Interaction	NNP	I-NP	O
Instruction	Instruction	NNP	I-NP	O
Give	Give	NNP	I-NP	O
on	on	IN	B-PP	O
an	an	DT	B-NP	O
empty	empty	JJ	I-NP	O
stomach	stomach	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
give	give	VBP	B-VP	O
1hr	1hr	NN	B-NP	O
before	before	IN	B-SBAR	O
or	or	CC	O	O
2hr	2hr	NN	B-NP	O
after	after	IN	B-SBAR	O
food	food	NN	B-NP	O
-RRB-	-RRB-	NNP	I-NP	O
Food	Food	NNP	I-NP	O
decreases	decrease	VBZ	B-VP	O
peak	peak	NN	B-NP	O
by	by	IN	B-PP	O
up	up	RB	B-NP	O
to	to	TO	I-NP	O
40	40	CD	I-NP	O
%	%	NN	I-NP	O
NABUMETONE	NABUMETONE	NN	I-NP	O
500	500	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
BID	BID	NNP	I-NP	O
Food/Drug	Food/Drug	NNP	I-NP	O
Interaction	Interaction	NNP	I-NP	O
Instruction	Instruction	NNP	I-NP	O
Take	Take	NNP	I-NP	O
with	with	IN	B-PP	O
food	food	NN	B-NP	B-DNA
PRAVACHOL	PRAVACHOL	NN	I-NP	I-DNA
-LRB-	-LRB-	NN	I-NP	I-DNA
PRAVASTATIN	PRAVASTATIN	NN	I-NP	I-DNA
-RRB-	-RRB-	NN	I-NP	I-DNA
20	20	CD	I-NP	I-DNA
MG	MG	NNP	I-NP	I-DNA
PO	PO	NNP	I-NP	I-DNA
BEDTIME	BEDTIME	NNP	I-NP	I-DNA
Food/Drug	Food/Drug	NNP	I-NP	I-DNA
Interaction	Interaction	NNP	I-NP	I-DNA
Instruction	Instruction	NNP	I-NP	I-DNA
Avoid	Avoid	NNP	I-NP	I-DNA
grapefruit	grapefruit	NN	I-NP	I-DNA
unless	unless	IN	B-SBAR	I-DNA
MD	MD	NN	B-NP	I-DNA
instructs	instruct	NNS	I-NP	I-DNA
otherwise	otherwise	RB	B-ADVP	O
.	.	.	O	O

Alert	Alert	NNP	B-NP	O
overridden	overridden	JJ	I-NP	O
:	:	:	O	O
Override	Override	NN	B-NP	O
added	add	VBN	B-VP	O
on	on	IN	B-PP	O
2/12/06	2/12/06	CD	B-NP	O
by	by	IN	B-PP	O
EMAMI	EMAMI	NN	B-NP	B-protein
,	,	,	O	O
HOLLIS	HOLLIS	NN	B-NP	O
,	,	,	O	O
M.D.	M.D.	NN	B-NP	O
on	on	IN	B-PP	O
order	order	NN	B-NP	O
for	for	IN	B-PP	O
PRAVACHOL	PRAVACHOL	NN	B-NP	O
PO	PO	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
ref	ref	NN	I-NP	O
#	#	#	B-NP	O
213792596	213792596	CD	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
Pt	Pt	NN	I-NP	O
.	.	.	O	O

has	have	VBZ	O	O
a	a	DT	B-NP	O
PROBABLE	PROBABLE	NN	I-NP	O
allergy	allergy	NN	I-NP	O
to	to	TO	B-PP	O
SIMVASTATIN	SIMVASTATIN	NN	B-NP	B-protein
;	;	:	O	O
reaction	reaction	NN	B-NP	O
is	be	VBZ	B-VP	O
muscle	muscle	NN	B-NP	O
aches	ache	NNS	I-NP	O
.	.	.	O	O

Reason	Reason	NN	B-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
patient	patient	NN	B-NP	O
requires	require	VBZ	B-VP	O
Previous	Previous	NNP	B-NP	O
Alert	Alert	NNP	I-NP	O
overridden	overridden	JJ	I-NP	O
Override	Override	NNP	I-NP	O
added	add	VBD	B-VP	O
on	on	IN	B-PP	O
2/12/06	2/12/06	CD	B-NP	O
by	by	IN	B-PP	O
YBOS	YBOS	NN	B-NP	B-protein
,	,	,	O	O
CLIFFORD	CLIFFORD	NN	B-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
CYCLOSPORINE	CYCLOSPORINE	NNP	B-NP	O
&	&	CC	I-NP	O
PRAVASTATIN	PRAVASTATIN	NNP	I-NP	O
SODIUM	SODIUM	NNP	I-NP	O
Reason	Reason	NNP	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
md	md	NN	B-NP	O
aware	aware	JJ	I-NP	O
PREDNISONE	PREDNISONE	NN	I-NP	O
6	6	CD	I-NP	O
MG	MG	NN	I-NP	O
PO	PO	NN	I-NP	O
QAM	QAM	NN	I-NP	O
DIET	DIET	NN	I-NP	O
:	:	:	O	O
House	House	NN	B-NP	O
/	/	SYM	O	O
ADA	ADA	NN	B-NP	O
2100	2100	CD	I-NP	O
cals/dy	cals/dy	NN	I-NP	O
ACTIVITY	ACTIVITY	NN	I-NP	O
:	:	:	O	O
Walking	Walk	VBG	B-VP	O
as	as	IN	B-SBAR	O
tolerated	tolerate	VBN	B-NP	O
FOLLOW	FOLLOW	NNP	I-NP	O
UP	UP	NNP	I-NP	O
APPOINTMENT	APPOINTMENT	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
S	S	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
:	:	:	O	O
Rheumatology	Rheumatology	NNP	B-NP	O
:	:	:	O	O
Dr.	Dr.	NNP	B-NP	O
Yoakum	Yoakum	NNP	I-NP	O
,	,	,	O	O
8540664703	8540664703	CD	B-NP	O
2	2	CD	I-NP	O
months	month	NNS	I-NP	O
time	time	NN	B-NP	O
,	,	,	O	O
Please	Please	NN	B-NP	B-protein
call	call	VB	B-VP	O
your	your	PRP$	B-NP	O
PCP	PCP	NN	I-NP	O
Dr.	Dr.	NNP	I-NP	O
Wardian	Wardian	NNP	I-NP	O
for	for	IN	B-PP	O
an	an	DT	B-NP	O
appointment	appointment	NN	I-NP	O
within	within	IN	B-PP	O
1-2	1-2	CD	B-NP	O
weeks	week	NNS	I-NP	O
of	of	IN	B-PP	O
discharge	discharge	NN	B-NP	O
-LRB-	-LRB-	HYPH	O	O
067-002-8011	067-002-8011	CD	B-NP	O
-RRB-	-RRB-	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
she	she	PRP	B-NP	O
may	may	MD	B-VP	O
refer	refer	VB	I-VP	O
you	you	PRP	B-NP	O
for	for	IN	B-PP	O
further	further	JJ	B-NP	O
diabetes	diabetes	NN	I-NP	O
care	care	NN	I-NP	O
,	,	,	O	O
ALLERGY	ALLERGY	NN	B-NP	O
:	:	:	O	O
SIMVASTATIN	SIMVASTATIN	NN	B-NP	O
ADMIT	ADMIT	NN	I-NP	O
DIAGNOSIS	DIAGNOSIS	NN	I-NP	O
:	:	:	O	O
L	L	NN	B-NP	O
Carotid	Carotid	NNP	I-NP	O
Artery	Artery	NNP	I-NP	O
Stent	Stent	NNP	I-NP	O
PRINCIPAL	PRINCIPAL	NNP	I-NP	O
DISCHARGE	DISCHARGE	NNP	I-NP	O
DIAGNOSIS	DIAGNOSIS	NNP	I-NP	O
;	;	:	O	O
Responsible	Responsible	JJ	B-ADJP	O
After	After	IN	B-PP	O
Study	Study	NNP	B-NP	O
for	for	IN	B-PP	O
Causing	Causing	NNP	B-NP	O
Admission	Admission	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
L	L	NNP	I-NP	O
Carotid	Carotid	NNP	I-NP	O
Artery	Artery	NNP	I-NP	O
Stent	Stent	NNP	I-NP	O
OTHER	OTHER	NNP	I-NP	O
DIAGNOSIS	DIAGNOSIS	NNP	I-NP	O
;	;	:	O	O
Conditions	Condition	NNS	B-NP	O
,	,	,	O	O
Infections	Infection	NNS	B-NP	O
,	,	,	O	O
Complications	Complication	NNS	B-NP	O
,	,	,	O	O
affecting	affect	VBG	B-VP	O
Treatment/Stay	Treatment/Stay	NNP	B-NP	O
s/p	s/p	NN	I-NP	O
cardiac	cardiac	JJ	I-NP	O
transplant	transplant	NN	I-NP	O
1992	1992	CD	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
S/P	S/P	NN	I-NP	O
cardiac	cardiac	JJ	I-NP	O
transplant	transplant	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
Diabetes	Diabetes	NN	I-NP	O
mellitus	mellitus	NN	I-NP	O
type	type	NN	I-NP	O
II	II	CD	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
diabetes	diabetes	NN	I-NP	O
mellitus	mellitus	NN	I-NP	O
type	type	NN	I-NP	O
2	2	CD	I-NP	O
-RRB-	-RRB-	HYPH	I-NP	O
Trochanteric	Trochanteric	JJ	I-NP	O
bursitis	bursitis	NN	I-NP	O
-LRB-	-LRB-	HYPH	B-NP	O
trochanteric	trochanteric	JJ	I-NP	O
bursitis	bursitis	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
Dyslipidemia	Dyslipidemia	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
dyslipidemia	dyslipidemia	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
DJD	DJD	NN	I-NP	O
spine	spine	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
OA	OA	NN	I-NP	O
of	of	IN	B-PP	O
cervical	cervical	JJ	B-NP	O
spine	spine	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
Hx	Hx	NN	I-NP	O
vocal	vocal	JJ	I-NP	O
cord	cord	NN	I-NP	O
injury	injury	NN	I-NP	O
postop	postop	VBP	B-VP	O
Hx	Hx	NN	B-NP	O
gastritis	gastritis	NN	I-NP	O
with	with	IN	B-PP	O
UGIB	UGIB	NN	B-NP	O
-LRB-	-LRB-	NN	I-NP	O
H/O	H/O	NN	I-NP	O
upper	upper	JJ	I-NP	O
GI	GI	NN	I-NP	O
bleeding	bleed	VBG	B-VP	O
-RRB-	-RRB-	NN	B-NP	O
Hx	Hx	NN	I-NP	O
postop	postop	VBP	B-VP	O
seizure	seizure	NN	B-NP	O
OPERATIONS	OPERATIONS	NNS	I-NP	O
AND	AND	CC	I-NP	O
PROCEDURES	PROCEDURES	NNS	I-NP	O
:	:	:	O	O
Left	Left	NNP	B-NP	O
Carotid	Carotid	NNP	I-NP	O
Artery	Artery	NNP	I-NP	O
Stent	Stent	NNP	I-NP	O
Placement	Placement	NNP	I-NP	O
.	.	.	O	O

OTHER	OTHER	NNP	B-NP	O
TREATMENTS/PROCEDURES	TREATMENTS/PROCEDURES	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
NOT	NOT	NNP	I-NP	O
IN	IN	NNP	I-NP	O
O.R.	O.R.	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
None	None	NNP	I-NP	O
.	.	.	O	O

BRIEF	BRIEF	NN	B-NP	O
RESUME	RESUME	NN	I-NP	O
OF	OF	IN	B-PP	O
HOSPITAL	HOSPITAL	JJ	B-NP	O
COURSE	COURSE	NN	I-NP	O
:	:	:	O	O
HPI	HPI	NN	B-NP	O
:	:	:	O	O
Ms.	Ms.	NNP	B-NP	O
Phetteplace	Phetteplace	NNP	I-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
70	70	CD	I-NP	O
yo	yo	NN	I-NP	O
woman	woman	NN	I-NP	O
with	with	IN	B-PP	O
h/o	h/o	NN	B-NP	O
Cardiac	Cardiac	JJ	I-NP	O
Transplant	Transplant	NN	I-NP	O
1992	1992	CD	I-NP	O
,	,	,	O	O
s/p	s/p	NN	B-NP	O
PCI/Stent	PCI/Stent	NN	I-NP	O
6/19	6/19	CD	I-NP	O
with	with	IN	B-PP	O
80	80	CD	B-NP	O
%	%	NN	I-NP	O
lesion	lesion	NN	I-NP	O
LCx	LCx	NN	I-NP	O
s/p	s/p	NN	I-NP	O
R	R	NNP	I-NP	O
Carotid	Carotid	NNP	I-NP	O
stent	stent	JJ	I-NP	O
placement	placement	NN	I-NP	O
6/19	6/19	CD	I-NP	O
,	,	,	O	O
h/o	h/o	NN	B-NP	O
DM	DM	NN	I-NP	O
,	,	,	O	O
HTN	HTN	NN	B-NP	B-protein
,	,	,	O	O
Hyperlipidemia	Hyperlipidemia	NN	B-NP	O
,	,	,	O	O
Smoking	Smoking	NN	B-NP	O
,	,	,	O	O
now	now	RB	B-ADVP	O
s/p	s/p	VBP	B-VP	O
L	L	NNP	B-NP	O
Carotid	Carotid	NNP	I-NP	O
Stent	Stent	NNP	I-NP	O
Placement	Placement	NNP	I-NP	O
10/24/06	10/24/06	CD	I-NP	O
.	.	.	O	O

During	During	IN	B-PP	O
annual	annual	JJ	B-NP	O
follow	follow	VB	B-VP	O
up	up	RP	B-PRT	O
in	in	IN	B-PP	O
9/30	9/30	CD	B-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
heart	heart	NN	I-NP	O
transplant	transplant	NN	I-NP	O
,	,	,	O	O
a	a	DT	B-NP	O
complex	complex	JJ	I-NP	O
eccentric	eccentric	JJ	I-NP	O
80	80	CD	I-NP	O
%	%	NN	I-NP	O
lesion	lesion	NN	I-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
proximal	proximal	JJ	I-NP	O
LCx	LCx	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
in	in	IN	B-PP	O
January	January	NNP	B-NP	O
electively	electively	RB	B-ADVP	O
with	with	IN	B-PP	O
plans	plan	NNS	B-NP	O
for	for	IN	B-PP	O
cardiac	cardiac	JJ	B-NP	O
cath/PCI/stent	cath/PCI/stent	NN	I-NP	O
.	.	.	O	O

However	However	RB	B-ADVP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
interim	interim	JJ	I-NP	O
period	period	NN	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
symptomatic	symptomatic	JJ	I-NP	O
LUE	LUE	NN	I-NP	O
numbness	numbness	NN	I-NP	O
thought	think	VBN	B-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
a	a	DT	B-NP	O
TIA	TIA	NN	I-NP	O
,	,	,	O	O
concerning	concern	VBG	B-VP	O
for	for	IN	B-PP	O
R	R	NN	B-NP	O
carotid	carotid	NN	I-NP	O
stenosis.An	stenosis.An	NN	I-NP	O
MRI	MRI	NN	I-NP	O
revealed	reveal	VBD	B-VP	O
bilateral	bilateral	JJ	B-NP	O
tight	tight	JJ	I-NP	O
carotid	carotid	NN	I-NP	O
stenosis	stenosis	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
LCx	LCx	NN	I-NP	B-protein
and	and	CC	I-NP	O
Symptomatic	Symptomatic	JJ	I-NP	O
R	R	NN	I-NP	O
Carotid	Carotid	NN	I-NP	O
artery	artery	NN	I-NP	O
underwent	undergo	VBD	B-VP	O
cath/stent	cath/stent	JJ	B-NP	O
placement	placement	NN	I-NP	O
in	in	IN	B-PP	O
6/19	6/19	CD	B-NP	O
.	.	.	O	O

However	However	RB	B-ADVP	O
,	,	,	O	O
intervention	intervention	NN	B-NP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
left	left	JJ	I-NP	B-protein
internal	internal	JJ	I-NP	I-protein
carotid	carotid	NN	I-NP	I-protein
artery	artery	NN	I-NP	I-protein
-LRB-	-LRB-	NN	I-NP	I-protein
though	though	IN	B-SBAR	O
90	90	CD	B-NP	O
%	%	NN	I-NP	O
occluded	occlude	VBN	B-VP	O
by	by	IN	B-PP	O
cath	cath	NN	B-NP	B-protein
-RRB-	-RRB-	NN	I-NP	I-protein
was	be	VBD	B-VP	O
deferred	defer	VBN	I-VP	O
due	due	JJ	B-ADJP	O
to	to	TO	B-VP	O
already	already	RB	I-VP	O
receiving	receive	VBG	I-VP	O
2	2	CD	B-NP	O
angiographikc	angiographikc	NN	I-NP	O
procedures	procedure	NNS	I-NP	O
during	during	IN	B-PP	O
the	the	DT	B-NP	O
6/19	6/19	CD	I-NP	O
admission	admission	NN	I-NP	O
.	.	.	O	O

At	At	IN	B-PP	O
this	this	DT	B-NP	O
time	time	NN	I-NP	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
tapered	taper	VBN	I-VP	O
off	off	RP	B-PRT	O
cell-cept	cell-cept	JJ	B-ADJP	O
and	and	CC	O	O
started	start	VBN	B-VP	O
on	on	IN	B-PP	O
rapamycin	rapamycin	NN	B-NP	O
-	-	HYPH	B-ADVP	O
in	in	IN	B-PP	O
hopes	hope	NNS	B-NP	O
of	of	IN	B-PP	O
slowing	slow	VBG	B-VP	O
progression	progression	NN	B-NP	O
in	in	IN	B-PP	O
her	her	PRP$	B-NP	O
coronary	coronary	JJ	I-NP	O
disease	disease	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
then	then	RB	B-ADVP	O
returned	return	VBD	B-VP	O
to	to	TO	B-PP	O
medical	medical	JJ	B-NP	O
attention	attention	NN	I-NP	O
on	on	IN	B-PP	O
19	19	CD	B-NP	O
of	of	IN	B-PP	O
April	April	NNP	B-NP	O
for	for	IN	B-PP	O
catheterization/stent	catheterization/stent	JJ	B-NP	O
placement	placement	NN	I-NP	O
on	on	IN	B-PP	O
Left	Left	NNP	B-NP	O
Carotid	Carotid	NNP	I-NP	O
Artery	Artery	NNP	I-NP	O
.	.	.	O	O

During	During	IN	B-PP	O
these	these	DT	B-NP	O
procedure	procedure	NN	I-NP	O
,	,	,	O	O
a	a	DT	B-NP	O
hematoma	hematoma	NN	I-NP	O
developed	develop	VBD	B-VP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
L	L	NN	I-NP	B-DNA
femoral	femoral	JJ	I-NP	I-DNA
access	access	NN	I-NP	I-DNA
site	site	NN	I-NP	I-DNA
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
managed	manage	VBN	I-VP	O
with	with	IN	B-PP	O
compression	compression	NN	B-NP	O
during	during	IN	B-PP	O
the	the	DT	B-NP	O
case	case	NN	I-NP	O
.	.	.	O	O

FSBS	FSBS	NNP	B-NP	O
was	be	VBD	B-VP	O
384	384	CD	B-NP	O
prior	prior	JJ	B-ADVP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
procedure	procedure	NN	I-NP	O
and	and	CC	O	O
elevated	elevate	VBN	B-VP	O
to	to	TO	B-PP	O
547	547	CD	B-NP	O
during	during	IN	B-PP	O
the	the	DT	B-NP	O
procedure	procedure	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
she	she	PRP	B-NP	O
received	receive	VBD	B-VP	O
D5W	D5W	NN	B-NP	B-protein
+	+	SYM	B-NP	O
HCO3	HCO3	NN	I-NP	B-protein
during	during	IN	B-PP	O
the	the	DT	B-NP	O
procedure	procedure	NN	I-NP	O
.	.	.	I-NP	O
-RRB-	-RRB-	NN	I-NP	B-protein

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
given	give	VBN	I-VP	O
10	10	CD	B-NP	O
u	u	NN	I-NP	O
regular	regular	JJ	I-NP	O
insulin	insulin	NN	I-NP	O
x	x	NN	I-NP	O
2	2	CD	I-NP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
FSBS	FSBS	NNP	I-NP	O
declined	decline	VBD	B-VP	O
to	to	TO	B-PP	O
400s	400s	CD	B-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
post-procedure	post-procedure	JJ	I-NP	O
course	course	NN	I-NP	O
has	have	VBZ	B-VP	O
been	be	VBN	I-VP	O
complicated	complicate	VBN	I-VP	O
by	by	IN	B-PP	O
hyperglycemia	hyperglycemia	NN	B-NP	O
and	and	CC	I-NP	O
hematoma	hematoma	NN	I-NP	O
formation	formation	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
Hct	Hct	NN	I-NP	O
drop	drop	NN	I-NP	O
of	of	IN	B-PP	O
30	30	CD	B-NP	O
`	`	``	I-NP	O
22	22	CD	I-NP	O
.	.	.	O	O

PMH	PMH	NN	B-NP	B-protein
:	:	:	O	I-protein
1	1	LS	B-LST	I-protein
.	.	.	O	O

TIA	TIA	NN	B-NP	O
Patient	Patient	NN	I-NP	O
taken	take	VBN	B-VP	O
to	to	TO	B-PP	O
cath	cath	NN	B-NP	B-protein
lab	lab	NN	I-NP	I-protein
after	after	IN	B-PP	O
RUE	RUE	NN	B-NP	O
numbness	numbness	NN	I-NP	O
c/w	c/w	NN	I-NP	O
TIA	TIA	NN	I-NP	O
6/19	6/19	CD	I-NP	O
.	.	.	O	O

Bilateral	Bilateral	JJ	B-NP	O
carotid	carotid	NN	I-NP	O
stenoses	stenosis	NNS	I-NP	O
were	be	VBD	B-VP	O
seen	see	VBN	I-VP	O
by	by	IN	B-PP	O
angiography	angiography	NN	B-NP	O
.	.	.	O	O

Stenting	Stenting	NN	B-NP	O
of	of	IN	B-PP	O
R	R	NN	B-NP	B-protein
internal	internal	JJ	I-NP	I-protein
carotid	carotid	NN	I-NP	I-protein
artery	artery	NN	I-NP	I-protein
performed	perform	VBD	B-VP	I-protein
2	2	CD	B-NP	I-protein
.	.	.	O	O

CAD	CAD	NN	B-NP	O
:	:	:	O	O
Coronary	Coronary	JJ	B-NP	O
angiography/PCI	angiography/PCI	NN	I-NP	O
of	of	IN	B-PP	O
LCx	LCx	NN	B-NP	O
lesion	lesion	NN	I-NP	O
.	.	.	O	O

Cypher	Cypher	NN	B-NP	O
stent	stent	NN	I-NP	O
.	.	.	O	O

Discharged	Discharge	VBN	B-VP	O
on	on	IN	B-PP	O
ASA/Plavix	ASA/Plavix	NNP	B-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Heart	Heart	NNP	B-NP	O
Transplant	Transplant	NNP	I-NP	O
Recipient	Recipient	NNP	I-NP	O
:	:	:	O	O
19922/2	19922/2	CD	B-NP	O
end	end	NN	I-NP	O
stage	stage	NN	I-NP	O
ischemic	ischemic	JJ	I-NP	O
cardiomyopathy	cardiomyopathy	NN	I-NP	O
.	.	.	O	O

Was	Be	VBD	B-VP	O
switched	switch	VBN	I-VP	O
from	from	IN	B-PP	O
cellcept	cellcept	NN	B-NP	O
and	and	CC	I-NP	O
cyclosporine	cyclosporine	NN	I-NP	O
to	to	TO	B-PP	O
rapamycin/cyclosporine	rapamycin/cyclosporine	NN	B-NP	O
during	during	IN	B-PP	O
6/19	6/19	CD	B-NP	O
admission	admission	NN	I-NP	O
because	because	IN	B-PP	O
of	of	IN	I-PP	O
concern	concern	NN	B-NP	O
of	of	IN	B-PP	O
progression	progression	NN	B-NP	O
of	of	IN	B-PP	O
coronary	coronary	JJ	B-NP	O
disease	disease	NN	I-NP	O
within	within	IN	B-PP	O
the	the	DT	B-NP	O
allograft	allograft	NN	I-NP	O
.	.	.	O	O

Last	Last	JJ	B-NP	O
Echo	Echo	NNP	I-NP	O
1/17	1/17	CD	I-NP	O
LV	LV	NN	I-NP	O
sized	sized	JJ	I-NP	O
decrease	decrease	NN	I-NP	O
,	,	,	O	O
normal	normal	JJ	B-NP	O
overall	overall	JJ	I-NP	O
function	function	NN	I-NP	O
.	.	.	O	O

EF	EF	NN	B-NP	O
65	65	CD	B-NP	O
%	%	NN	I-NP	O
.	.	.	O	O

No	No	DT	B-NP	O
RWMA	RWMA	NN	I-NP	B-protein
.	.	.	O	O

RV	RV	NN	B-NP	O
Nl	Nl	NN	I-NP	O
Size/thickness/function	Size/thickness/function	NN	I-NP	O
.	.	.	O	O

Severe	Severe	JJ	B-NP	O
LAE/Mild	LAE/Mild	NN	I-NP	O
RAE	RAE	NN	I-NP	O
c/w	c/w	NN	I-NP	O
transplant	transplant	NN	I-NP	O
.	.	.	O	O

No	No	DT	B-NP	O
change	change	NN	I-NP	O
from	from	IN	B-PP	O
10/4	10/4	CD	B-NP	O
study	study	NN	I-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Hypercholesterolemia	Hypercholesterolemia	NN	B-NP	B-protein
5	5	CD	I-NP	I-protein
.	.	.	O	O

DJD	DJD	NN	B-NP	O
Spine	Spine	NN	I-NP	O
6	6	CD	I-NP	O
.	.	.	O	O

Type	Type	NN	B-NP	B-protein
II	II	CD	I-NP	I-protein
DM	DM	NN	I-NP	I-protein
since	since	IN	B-PP	O
1992	1992	CD	B-NP	O
7	7	CD	I-NP	O
.	.	.	O	O

Gastritis	Gastritis	NN	B-NP	B-protein
8	8	CD	I-NP	I-protein
.	.	.	O	O

H/o	H/o	NN	B-NP	O
GIB	GIB	NN	I-NP	O
Meds	Med	NNS	I-NP	O
on	on	IN	B-PP	O
Admission	Admission	NN	B-NP	O
:	:	:	O	O
Rapamune	Rapamune	NNP	B-NP	O
1	1	CD	I-NP	O
mg	mg	NN	I-NP	O
BID	BID	NN	I-NP	O
,	,	,	O	O
Prednisone	Prednisone	NN	B-NP	O
6	6	CD	I-NP	O
mg	mg	NN	I-NP	O
Qday	Qday	NNP	B-NP	O
,	,	,	O	O
Metoprolol	Metoprolol	NNP	B-NP	O
50	50	CD	I-NP	O
mg	mg	NN	I-NP	O
PO	PO	NNP	I-NP	O
QDAy	QDAy	NNP	I-NP	O
,	,	,	O	O
Zantac	Zantac	NNP	B-NP	O
150	150	CD	I-NP	O
mg	mg	NN	I-NP	O
PO	PO	NNP	I-NP	O
BID	BID	NNP	I-NP	O
,	,	,	O	O
Nabumetone	Nabumetone	NNP	B-NP	O
750	750	CD	I-NP	O
QDay	QDay	NNP	I-NP	O
,	,	,	I-NP	O
Glyburide	Glyburide	NNP	I-NP	O
5	5	CD	I-NP	O
mg	mg	NN	I-NP	O
BID	BID	NNP	I-NP	O
,	,	,	O	O
Ditropan	Ditropan	NNP	B-NP	O
10	10	CD	I-NP	O
mg	mg	NN	I-NP	O
PO	PO	NNP	I-NP	O
Qday	Qday	NNP	I-NP	O
,	,	,	O	O
Plavix	Plavix	NNP	B-NP	O
75	75	CD	I-NP	O
mg	mg	NN	I-NP	O
PO	PO	NNP	I-NP	O
Qday	Qday	NNP	I-NP	O
,	,	,	O	O
Zetia	Zetia	NNP	B-NP	O
10	10	CD	I-NP	O
mg	mg	NN	I-NP	O
PO	PO	NNP	I-NP	O
Qday	Qday	NNP	I-NP	O
,	,	,	I-NP	O
Lasix	Lasix	NNP	I-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
PO	PO	NNP	I-NP	O
Qday	Qday	NNP	I-NP	O
,	,	,	O	O
Tums	Tums	NNP	B-NP	O
PO	PO	NNP	I-NP	O
TID	TID	NNP	I-NP	O
,	,	,	O	O
ECASA	ECASA	NNP	B-NP	O
325	325	CD	I-NP	O
,	,	,	O	O
Magnesium	Magnesium	NNP	B-NP	O
400	400	CD	I-NP	O
mg	mg	NN	I-NP	O
PO	PO	NNP	I-NP	O
Qday	Qday	NNP	I-NP	O
,	,	,	O	O
Multivit	Multivit	NNP	B-NP	O
,	,	,	O	O
Cyclosporine	Cyclosporine	NNP	B-NP	O
50	50	CD	I-NP	O
mg	mg	NN	I-NP	O
PO	PO	NNP	I-NP	O
BID	BID	NNP	I-NP	O
,	,	,	O	O
Tricor	Tricor	NNP	B-NP	O
48	48	CD	I-NP	O
mg	mg	NN	I-NP	O
PO	PO	NNP	I-NP	O
QDay	QDay	NNP	I-NP	O
Soc	Soc	NNP	I-NP	O
Hx	Hx	NNP	I-NP	O
:	:	:	O	O
ExSmoker	ExSmoker	NNP	B-NP	O
and	and	CC	O	O
drinks	drink	VBZ	B-VP	O
wine	wine	NN	B-NP	O
occassionally	occassionally	RB	B-ADVP	O
.	.	.	O	O

She	She	PRP	B-NP	O
lives	live	VBZ	B-VP	O
alone	alone	RB	B-ADVP	O
.	.	.	O	O

All	All	DT	B-NP	O
:	:	:	O	O
Prior	Prior	JJ	B-NP	O
Intolerance	Intolerance	NN	I-NP	O
of	of	IN	B-PP	O
Statins	Statin	NNS	B-NP	B-protein
-LRB-	-LRB-	CC	O	O
full	full	JJ	B-NP	O
body	body	NN	I-NP	O
aches	ache	VBZ	B-VP	O
-RRB-	-RRB-	NNP	B-NP	O
and	and	CC	I-NP	O
Zetia	Zetia	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
muscular	muscular	JJ	I-NP	O
aches	ache	NNS	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
.	.	.	O	O

Exam	Exam	NN	B-NP	O
on	on	IN	B-PP	O
5/25/06	5/25/06	CD	B-NP	O
Vitals	Vitals	NNP	I-NP	O
-	-	HYPH	I-NP	O
Afebrile	Afebrile	NNP	I-NP	O
96/52	96/52	CD	I-NP	O
95	95	CD	I-NP	O
No	No	DT	B-NP	O
JVD	JVD	NN	I-NP	B-protein
,	,	,	O	O
neck	neck	NN	B-NP	O
supple	supple	NN	I-NP	O
,	,	,	O	O
CTAB	CTAB	NN	B-NP	B-protein
,	,	,	O	O
Distant	Distant	JJ	B-NP	O
heart	heart	NN	I-NP	O
sounds	sound	VBZ	B-VP	O
RRR	RRR	NN	B-NP	B-protein
.	.	.	O	O

No	No	DT	B-NP	O
M/R/G	M/R/G	NN	I-NP	B-protein
appreciated	appreciate	VBN	B-VP	O
,	,	,	O	O
Soft	Soft	NNP	B-NP	O
NT/ND	NT/ND	NNP	I-NP	O
.	.	.	O	O

R	R	NN	B-NP	B-protein
Groin	Groin	NN	I-NP	I-protein
-	-	HYPH	B-NP	O
ecchymosis	ecchymosis	NN	I-NP	O
,	,	,	O	O
no	no	DT	B-NP	O
marked	marked	JJ	I-NP	O
swelling/hematoma	swelling/hematoma	NN	I-NP	O
at	at	IN	B-PP	O
site	site	NN	B-NP	O
.	.	.	O	O

Extremities	Extremity	NNS	B-NP	O
:	:	:	O	O
Tr	Tr	NN	B-NP	O
edema	edema	NN	I-NP	O
,	,	,	O	O
+1	+1	CC	O	O
pulses	pulse	VBZ	B-VP	O
DP/AT	DP/AT	NN	B-NP	B-protein
bilaterally	bilaterally	RB	B-ADVP	O
.	.	.	O	O

Assessment	Assessment	NN	B-NP	O
:	:	:	O	O
Ms.	Ms.	NNP	B-NP	O
Poehlein	Poehlein	NNP	I-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
70	70	CD	I-NP	O
yo	yo	NN	I-NP	O
woman	woman	NN	I-NP	O
with	with	IN	B-PP	O
h/o	h/o	NN	B-NP	O
Cardiac	Cardiac	JJ	I-NP	O
Transplant	Transplant	NN	I-NP	O
1992	1992	CD	I-NP	O
,	,	,	O	O
s/p	s/p	NN	B-NP	O
PCI/Stent	PCI/Stent	NN	I-NP	O
6/19	6/19	CD	I-NP	O
with	with	IN	B-PP	O
80	80	CD	B-NP	O
%	%	NN	I-NP	O
lesion	lesion	NN	I-NP	O
LCx	LCx	NN	I-NP	O
s/p	s/p	NN	I-NP	O
R	R	NNP	I-NP	O
Carotid	Carotid	NNP	I-NP	O
stent	stent	JJ	I-NP	O
placement	placement	NN	I-NP	O
6/19	6/19	CD	I-NP	O
,	,	,	O	O
h/o	h/o	NN	B-NP	O
DM	DM	NN	I-NP	O
,	,	,	O	O
HTN	HTN	NN	B-NP	B-protein
,	,	,	O	O
Hyperlipidemia	Hyperlipidemia	NN	B-NP	O
,	,	,	O	O
Smoking	Smoking	NN	B-NP	O
,	,	,	O	O
now	now	RB	B-ADVP	O
s/p	s/p	VBP	B-VP	O
L	L	NNP	B-NP	O
Carotid	Carotid	NNP	I-NP	O
Stent	Stent	NNP	I-NP	O
Placement	Placement	NNP	I-NP	O
10/24/06	10/24/06	CD	I-NP	O
with	with	IN	B-PP	O
postprocedure	postprocedure	JJ	B-NP	O
course	course	NN	I-NP	O
complicated	complicate	VBN	B-VP	O
by	by	IN	B-PP	O
hematoma	hematoma	NN	B-NP	O
formation	formation	NN	I-NP	O
causing	cause	VBG	B-VP	O
acute	acute	JJ	B-ADJP	O
on	on	IN	B-PP	O
chronic	chronic	JJ	B-NP	O
anemia	anemia	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
hyperglycemia	hyperglycemia	NN	B-NP	O
.	.	.	O	O

Labs/Studies	Labs/Study	NNS	B-NP	O
:	:	:	O	O
Chol	Chol	NN	B-NP	O
:	:	:	O	O
Chol	Chol	NN	B-NP	O
354	354	CD	I-NP	O
,	,	,	O	O
TG	TG	NN	B-NP	O
1383	1383	CD	I-NP	O
,	,	,	O	O
HDL	HDL	NN	B-NP	O
29	29	CD	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
Up	Up	NN	I-NP	O
from	from	IN	B-PP	O
4/11	4/11	CD	B-NP	O
Chol	Chol	NN	I-NP	O
267	267	CD	B-NP	O
,	,	,	O	O
TG	TG	NN	B-NP	B-cell_line
677	677	CD	I-NP	I-cell_line
,	,	,	O	O
HDL	HDL	NN	B-NP	O
29	29	CD	I-NP	O
-RRB-	-RRB-	:	O	O
HbA1c	HbA1c	NN	B-NP	B-protein
11.1	11.1	CD	B-NP	I-protein
-LRB-	-LRB-	NN	I-NP	I-protein
up	up	RB	B-ADVP	O
from	from	IN	B-PP	O
10/18	10/18	CD	B-NP	O
6.9	6.9	CD	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
1	1	CD	I-NP	O
.	.	.	O	O

Heme	Heme	NN	B-NP	B-protein
:	:	:	O	O
Patient	Patient	NN	B-NP	O
had	have	VBD	B-VP	O
r	r	JJ	B-NP	O
femoral	femoral	JJ	I-NP	O
hematoma	hematoma	NN	I-NP	O
due	due	JJ	B-ADJP	O
to	to	TO	B-PP	O
bleeding	bleed	VBG	B-VP	O
around	around	IN	B-PP	O
sheath	sheath	NN	B-NP	O
and	and	CC	O	O
causing	cause	VBG	B-VP	O
fluctuation	fluctuation	NN	B-NP	O
in	in	IN	B-PP	O
Hct	Hct	NN	B-NP	B-protein
.	.	.	O	O

HCT	HCT	NN	B-NP	O
currently	currently	RB	B-ADJP	O
stable	stable	JJ	I-ADJP	O
without	without	IN	B-PP	O
transfusions	transfusion	NNS	B-NP	O
.	.	.	O	O

Site	Site	NN	B-NP	O
non-pulsatile	non-pulsatile	JJ	I-NP	O
and	and	CC	O	O
no	no	DT	B-NP	O
bruits	bruit	NNS	I-NP	O
.	.	.	O	O

Transfusing	Transfuse	VBG	B-VP	O
1	1	CD	B-NP	O
U	U	NN	I-NP	O
pRBC	pRBC	NN	I-NP	O
6/20	6/20	CD	I-NP	O
for	for	IN	B-PP	O
goal	goal	NN	B-NP	O
Hct	Hct	NN	I-NP	O
>	>	SYM	B-NP	O
28	28	CD	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

CV	CV	NN	B-NP	O
-LRB-	-LRB-	NNP	I-NP	O
Ischemia	Ischemia	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
:	:	:	O	O
Patient	Patient	NNP	B-NP	O
h/o	h/o	NN	I-NP	O
ischemic	ischemic	JJ	I-NP	O
CM	CM	NN	I-NP	O
s/p	s/p	NN	I-NP	O
heart	heart	NN	I-NP	O
transplant	transplant	NN	I-NP	O
with	with	IN	B-PP	O
evidence	evidence	NN	B-NP	O
of	of	IN	B-PP	O
CAD	CAD	NN	B-NP	O
on	on	IN	B-PP	O
allograft	allograft	NN	B-NP	O
.	.	.	O	O

Patient	Patient	NN	B-NP	O
medically	medically	RB	B-VP	O
managed	manage	VBN	I-VP	O
with	with	IN	B-PP	O
pravachol	pravachol	NN	B-NP	O
,	,	,	I-NP	O
aspirin	aspirin	NN	I-NP	O
and	and	CC	I-NP	O
plavix	plavix	NN	I-NP	O
.	.	.	O	O

Now	Now	RB	B-ADVP	O
s/p	s/p	VB	B-VP	O
bilateral	bilateral	JJ	B-NP	O
carotid	carotid	NN	I-NP	O
stents	stent	NNS	I-NP	O
and	and	CC	O	O
stent	stent	NN	B-NP	O
to	to	TO	B-PP	O
LCx	LCx	NN	B-NP	B-protein
.	.	.	O	O

Attempt	Attempt	VB	B-VP	O
to	to	TO	I-VP	O
change	change	VB	I-VP	O
immunosuppressive	immunosuppressive	JJ	B-NP	O
regiments	regiment	NNS	I-NP	O
to	to	TO	B-PP	O
rapamycin	rapamycin	NN	B-NP	O
in	in	IN	B-SBAR	O
order	order	NN	O	O
to	to	TO	B-PP	O
lower	low	JJR	B-NP	O
progression	progression	NN	I-NP	O
of	of	IN	B-PP	O
CAD	CAD	NN	B-NP	B-protein
however	however	RB	B-ADVP	O
on	on	IN	B-PP	O
this	this	DT	B-NP	O
regiment	regiment	NN	I-NP	O
,	,	,	O	O
her	her	PRP$	B-NP	O
cholesterol	cholesterol	NN	I-NP	O
panel	panel	NN	I-NP	O
has	have	VBZ	B-VP	O
markedly	markedly	RB	I-VP	O
worsened	worsen	VBN	I-VP	O
.	.	.	O	O

Have	Have	NNP	B-NP	O
stopped	stop	VBD	B-VP	O
rapamycin	rapamycin	NN	B-NP	B-protein
-LRB-	-LRB-	HYPH	O	I-protein
6/20	6/20	CD	B-NP	I-protein
-RRB-	-RRB-	NN	I-NP	I-protein
and	and	CC	O	O
restarting	restart	VBG	B-VP	O
cellcept	cellcept	NN	B-NP	O
and	and	CC	I-NP	O
cyclosporine	cyclosporine	NN	I-NP	O
at	at	IN	B-PP	O
prior	prior	JJ	B-NP	O
doses	dose	NNS	I-NP	O
.	.	.	O	O

Will	Will	MD	B-VP	O
need	need	VB	I-VP	O
review	review	NN	B-NP	O
in	in	IN	B-PP	O
clinic	clinic	NN	B-NP	O
in	in	IN	B-PP	O
30	30	CD	B-NP	O
days	day	NNS	I-NP	O
with	with	IN	B-PP	O
bilateral	bilateral	JJ	B-NP	O
carotid	carotid	NN	I-NP	O
ultrasounds	ultrasound	NNS	I-NP	O
.	.	.	O	O

CV	CV	NNP	B-NP	O
-LRB-	-LRB-	NNP	I-NP	O
Pump	Pump	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
:	:	:	O	O
Clinically	Clinically	NNP	B-NP	O
appears	appear	VBZ	B-VP	O
euvolemic	euvolemic	JJ	B-ADJP	O
.	.	.	O	O

On	On	IN	B-PP	O
Toprol	Toprol	NNP	B-NP	O
,	,	,	O	O
restarting	restart	VBG	B-VP	O
lasix	lasix	NN	B-NP	O
at	at	IN	B-PP	O
home	home	NN	B-NP	B-protein
dose	dose	NN	I-NP	I-protein
-LRB-	-LRB-	HYPH	O	I-protein
5/13	5/13	CD	B-NP	I-protein
-RRB-	-RRB-	NN	I-NP	I-protein
.	.	.	O	O

CV	CV	NN	B-NP	O
-LRB-	-LRB-	NNP	I-NP	O
Rhythm	Rhythm	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
:	:	:	O	O
On	On	IN	B-PP	O
telemetry	telemetry	NN	B-NP	O
,	,	,	O	O
no	no	DT	B-NP	O
events	event	NNS	I-NP	O
seen	see	VBN	B-VP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Endo	Endo	NNP	B-NP	O
:	:	:	O	O
During	During	IN	B-PP	O
hospitalization	hospitalization	NN	B-NP	O
and	and	CC	O	O
prior/during	prior/dure	VBG	B-NP	O
procedures	procedure	NNS	I-NP	O
has	have	VBZ	B-VP	O
had	have	VBN	I-VP	O
poor	poor	JJ	B-NP	O
glucose	glucose	NN	I-NP	O
controls	control	NNS	I-NP	O
with	with	IN	B-PP	O
FSBS	FSBS	NNP	B-NP	B-protein
in	in	IN	B-PP	O
300s-400s	300s-400s	CD	B-NP	O
.	.	.	O	O

Patient	Patient	NN	B-NP	O
reports	report	VBZ	B-VP	O
poor	poor	JJ	B-NP	O
glycemic	glycemic	JJ	I-NP	O
control	control	NN	I-NP	O
at	at	IN	B-PP	O
home	home	NN	B-NP	O
with	with	IN	B-PP	O
FSBS	FSBS	NNP	B-NP	B-protein
in	in	IN	B-PP	O
300s	300s	CD	B-NP	O
.	.	.	O	O

AM	AM	NNP	B-NP	O
FSBS	FSBS	NNP	I-NP	O
was	be	VBD	B-VP	O
384	384	CD	B-NP	O
and	and	CC	O	O
received	receive	VBD	B-VP	O
D5NS	D5NS	NN	B-NP	O
prior	prior	JJ	B-ADJP	O
to	to	TO	B-VP	O
procedure	procedure	VB	I-VP	O
,	,	,	O	O
exacerbating	exacerbate	VBG	B-VP	O
hyperglycemia	hyperglycemia	NN	B-NP	O
.	.	.	O	O

Endocrinconsulted	Endocrinconsulte	VBD	O	O
and	and	CC	O	O
recommended	recommend	VBD	B-VP	O
Qday	Qday	NNP	B-NP	O
lantus	lantus	NN	I-NP	O
injection	injection	NN	I-NP	O
with	with	IN	B-PP	O
with	with	IN	B-PP	O
Novolog	Novolog	NN	B-NP	O
sliding	slide	VBG	B-VP	O
scale	scale	NN	B-NP	O
+	+	SYM	B-NP	O
AC	AC	NN	I-NP	O
while	while	IN	B-SBAR	O
in	in	IN	B-PP	O
house	house	NN	B-NP	O
.	.	.	O	O

HbA1c	HbA1c	NN	B-NP	B-protein
@	@	NN	I-NP	I-protein
11	11	CD	I-NP	I-protein
-LRB-	-LRB-	:	O	I-protein
markedly	markedly	RB	B-ADJP	O
worse	worse	JJR	I-ADJP	O
than	than	IN	B-PP	O
6	6	CD	B-NP	O
in	in	IN	B-PP	O
January	January	NNP	B-NP	O
-RRB-	-RRB-	NNP	I-NP	O
-	-	HYPH	B-NP	O
patient	patient	NN	I-NP	O
can	can	MD	B-VP	O
not	not	RB	I-VP	O
identify	identify	VB	I-VP	O
other	other	JJ	B-NP	O
factors	factor	NNS	I-NP	O
which	which	WDT	B-NP	O
have	have	VBP	B-VP	O
changed	change	VBN	I-VP	O
since	since	IN	B-PP	O
January	January	NNP	B-NP	O
other	other	JJ	B-ADJP	O
than	than	IN	B-SBAR	O
immunosuppressants	immunosuppressant	NNS	B-NP	O
to	to	TO	B-PP	O
rapamycin	rapamycin	NN	B-NP	O
.	.	.	O	O

FSBS	FSBS	NNP	B-NP	O
were	be	VBD	B-VP	O
difficult	difficult	JJ	B-ADJP	O
to	to	TO	B-VP	O
control	control	VB	I-VP	O
in	in	IN	B-PP	O
house	house	NN	B-NP	O
despite	despite	IN	B-PP	O
using	use	VBG	B-VP	O
20	20	CD	B-NP	O
QDay	QDay	NN	I-NP	O
of	of	IN	B-PP	O
lantus	lantus	NN	B-NP	O
,	,	,	O	O
Ms.	Ms.	NNP	B-NP	O
Nickodem	Nickodem	NNP	I-NP	O
FSBS	FSBS	NNP	I-NP	O
continued	continue	VBD	B-VP	O
to	to	TO	I-VP	O
run	run	VB	I-VP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
200s-300s	200s-300s	CD	I-NP	O
during	during	IN	B-PP	O
the	the	DT	B-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
taught	teach	VBN	I-VP	O
to	to	TO	I-VP	O
inject	inject	VB	I-VP	O
herself	herself	PRP	B-NP	O
with	with	IN	B-PP	O
insulin	insulin	NN	B-NP	B-protein
SC	SC	NN	I-NP	I-protein
during	during	IN	B-PP	O
her	her	PRP$	B-NP	O
stay	stay	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
is	be	VBZ	B-VP	O
discharged	discharge	VBN	I-VP	O
on	on	IN	B-PP	O
Glyburide	Glyburide	NN	B-NP	O
10	10	CD	I-NP	O
QDay	QDay	NNP	I-NP	O
and	and	CC	I-NP	O
Lantus	Lantus	NNP	I-NP	O
20	20	CD	I-NP	O
QDay	QDay	NNP	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
taught	teach	VBN	I-VP	O
to	to	TO	I-VP	O
keep	keep	VB	I-VP	O
a	a	DT	B-NP	O
diary	diary	NN	I-NP	O
and	and	CC	O	O
will	will	MD	B-VP	O
follow	follow	VB	I-VP	O
up	up	RP	B-PRT	O
with	with	IN	B-PP	O
her	her	PRP$	B-NP	O
PCP	PCP	NN	I-NP	B-protein
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Neuro	Neuro	NNP	B-NP	O
:	:	:	O	O
TIA/CVA	TIA/CVA	NN	B-NP	O
in	in	IN	B-PP	O
6/19	6/19	CD	B-NP	O
.	.	.	O	O

residual	residual	JJ	B-NP	O
Left	Left	NNP	I-NP	O
numbness/weakness	numbness/weakness	NN	I-NP	O
in	in	IN	B-PP	O
hand	hand	NN	B-NP	O
.	.	.	O	O

On	On	IN	B-PP	O
plavix	plavix	NN	B-NP	O
and	and	CC	I-NP	O
asa	asa	NN	I-NP	O
,	,	,	O	O
now	now	RB	B-ADVP	O
s/p	s/p	VBP	B-VP	O
R	R	NNP	B-NP	O
and	and	CC	I-NP	O
L	L	NNP	I-NP	O
Carotid	Carotid	NNP	I-NP	O
Stents	Stents	NNP	I-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Immunosuppression	Immunosuppression	NN	B-NP	O
:	:	:	O	O
As	As	IN	B-PP	O
above	above	RB	B-ADVP	O
,	,	,	O	O
have	have	VBP	B-VP	O
changed	change	VBN	I-VP	O
immunosuppression	immunosuppression	NN	B-NP	O
from	from	IN	B-PP	O
Rapamycin	Rapamycin	NN	B-NP	O
+	+	SYM	B-VP	O
Cyclosporine	Cyclosporine	NN	B-NP	O
back	back	RB	B-ADVP	O
to	to	TO	B-PP	O
Cyclosporine	Cyclosporine	NN	B-NP	O
75	75	CD	I-NP	O
BID	BID	NN	I-NP	O
+	+	SYM	B-NP	O
Cellcept	Cellcept	NN	B-NP	O
1000	1000	CD	I-NP	O
BID	BID	NN	I-NP	O
as	as	IN	B-SBAR	O
patient	patient	NN	B-NP	O
performed	perform	VBD	B-VP	O
priorto	priorto	RB	B-NP	O
6/19	6/19	CD	I-NP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

MSK/Rheum	MSK/Rheum	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
previously	previously	RB	B-VP	O
complained	complain	VBN	I-VP	O
of	of	IN	B-PP	O
myalgias	myalgia	NNS	B-NP	O
with	with	IN	B-PP	O
statins	statin	NNS	B-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
resistant	resistant	JJ	B-ADJP	O
to	to	TO	B-PP	O
starting	start	VBG	B-VP	O
statins	statin	NNS	B-NP	O
because	because	IN	B-SBAR	O
they	they	PRP	B-NP	O
seemed	seem	VBD	B-VP	O
to	to	TO	I-VP	O
worsen	worsen	VB	I-VP	O
her	her	PRP$	B-NP	O
aches/pains	aches/pain	NNS	I-NP	O
.	.	.	O	O

Rheumatology	Rheumatology	NN	B-NP	O
service	service	NN	I-NP	O
was	be	VBD	B-VP	O
consulted	consult	VBN	I-VP	O
.	.	.	O	O

They	They	PRP	B-NP	O
believed	believe	VBD	B-VP	O
her	her	PRP$	B-NP	O
pain	pain	NN	I-NP	O
is	be	VBZ	B-VP	O
not	not	RB	O	O
consistent	consistent	JJ	B-ADJP	O
with	with	IN	B-PP	O
statin	statin	NN	B-NP	O
associated	associate	VBN	I-NP	O
myalgia	myalgia	NN	I-NP	O
.	.	.	O	O

Zetia	Zetia	NN	B-NP	O
was	be	VBD	B-VP	O
stopped	stop	VBN	I-VP	O
and	and	CC	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
Pravachol	Pravachol	NN	B-NP	O
20	20	CD	I-NP	O
mg	mg	NN	I-NP	O
QHS	QHS	NNP	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	B-protein
back	back	JJ	I-NP	I-protein
pain	pain	NN	I-NP	I-protein
is	be	VBZ	B-VP	O
relieved	relieve	VBN	I-VP	O
by	by	IN	B-PP	O
leaning	lean	VBG	B-VP	O
forward	forward	RB	B-ADVP	O
and	and	CC	O	O
she	she	PRP	B-NP	O
walks	walk	VBZ	B-VP	O
at	at	IN	B-PP	O
Arkansas	Arkansas	NNP	B-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
shopping	shopping	NN	I-NP	O
cart	cart	NN	I-NP	O
for	for	IN	B-PP	O
exercise	exercise	NN	B-NP	O
which	which	WDT	B-NP	O
is	be	VBZ	B-VP	O
consistent	consistent	JJ	B-ADJP	O
with	with	IN	B-PP	O
spinal	spinal	JJ	B-NP	O
stenosis	stenosis	NN	I-NP	O
.	.	.	O	O

They	They	PRP	B-NP	O
recommended	recommend	VBD	B-VP	O
physical	physical	JJ	B-NP	O
therapy	therapy	NN	I-NP	O
and	and	CC	I-NP	O
MRI	MRI	NN	I-NP	O
imaging	imaging	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
back	back	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
MRI	MRI	NN	I-NP	O
preliminary	preliminary	JJ	I-NP	O
read	read	NN	I-NP	O
shows	show	VBZ	B-VP	O
multilevel	multilevel	JJ	B-NP	O
degenerative	degenerative	JJ	I-NP	O
disc	disc	NN	I-NP	O
disease	disease	NN	I-NP	O
and	and	CC	O	O
moderate	moderate	JJ	B-NP	O
spinal	spinal	JJ	I-NP	O
stenosis	stenosis	NN	I-NP	O
at	at	IN	B-PP	O
one	one	CD	B-NP	O
level	level	NN	I-NP	O
.	.	.	O	O

Physical	Physical	JJ	B-NP	O
therapy	therapy	NN	I-NP	O
saw	see	VBD	B-VP	O
her	her	PRP	B-NP	O
and	and	CC	O	O
thought	think	VBD	B-VP	O
she	she	PRP	B-NP	O
would	would	MD	B-VP	O
benefit	benefit	VB	I-VP	O
from	from	IN	B-PP	O
home	home	NN	B-NP	O
PT	PT	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
future	future	NN	I-NP	O
--	--	:	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
given	give	VBN	I-VP	O
a	a	DT	B-NP	O
prescription	prescription	NN	I-NP	O
for	for	IN	B-PP	O
outpatient	outpatient	NN	B-NP	O
physical	physical	JJ	I-NP	O
therapy	therapy	NN	I-NP	O
.	.	.	O	O

Since	Since	IN	B-SBAR	O
she	she	PRP	B-NP	O
is	be	VBZ	B-VP	O
on	on	IN	B-PP	O
long	long	JJ	B-NP	O
term	term	NN	I-NP	O
prednisone	prednisone	NN	I-NP	O
she	she	PRP	B-NP	O
should	should	MD	B-VP	O
have	have	VB	I-VP	O
a	a	DT	B-NP	O
DEXA	DEXA	NN	I-NP	O
scan	scan	NN	I-NP	O
and	and	CC	O	O
may	may	MD	B-VP	O
benefit	benefit	VB	I-VP	O
from	from	IN	B-PP	O
bisphosphonate	bisphosphonate	JJ	B-NP	O
therapy	therapy	NN	I-NP	O
.	.	.	O	O

Discharge	Discharge	NNP	B-NP	O
Medication	Medication	NNP	I-NP	O
:	:	:	O	O
Cellcept	Cellcept	NNP	B-NP	O
1000	1000	CD	B-NP	O
mg	mg	NN	I-NP	O
BID	BID	NNP	B-NP	O
,	,	,	O	O
Lantus	Lantus	NNP	B-NP	O
20	20	CD	I-NP	O
SC	SC	NNP	I-NP	O
QAM	QAM	NNP	I-NP	O
,	,	,	O	O
Nabumetone	Nabumetone	NNP	B-NP	O
500	500	CD	I-NP	O
mg	mg	NN	I-NP	O
PO	PO	NN	I-NP	O
BID	BID	NN	I-NP	O
,	,	,	O	O
Pravachol	Pravachol	NN	B-NP	O
20	20	CD	I-NP	O
mg	mg	NN	I-NP	O
PO	PO	NNP	I-NP	O
QHS	QHS	NNP	I-NP	O
,	,	,	O	O
Glyburide	Glyburide	NNP	B-NP	O
10	10	CD	I-NP	O
mg	mg	NN	I-NP	O
PO	PO	NN	I-NP	O
QAM	QAM	NN	I-NP	O
,	,	,	O	O
Cyclosporine	Cyclosporine	NN	B-NP	O
75	75	CD	I-NP	O
mg	mg	NN	I-NP	O
PO	PO	NNP	I-NP	O
BID	BID	NNP	I-NP	O
,	,	,	O	O
Toprol	Toprol	NNP	B-NP	O
50	50	CD	I-NP	O
mg	mg	NN	I-NP	O
PO	PO	NNP	I-NP	O
QDay	QDay	NNP	I-NP	O
,	,	,	O	O
Prednisone	Prednisone	NNP	B-NP	O
6	6	CD	I-NP	O
mg	mg	NN	I-NP	O
PO	PO	NNP	I-NP	O
QAM	QAM	NNP	I-NP	O
,	,	,	O	O
Plavix	Plavix	NNP	B-NP	O
75	75	CD	I-NP	O
PO	PO	NNP	I-NP	O
QDay	QDay	NNP	I-NP	O
,	,	,	O	O
Zantac	Zantac	NNP	B-NP	O
150	150	CD	I-NP	O
mg	mg	NN	I-NP	O
BID	BID	NNP	I-NP	O
,	,	,	I-NP	O
Furosemide	Furosemide	NNP	I-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
PO	PO	NNP	I-NP	O
QDay	QDay	NNP	I-NP	O
,	,	,	O	O
Fe	Fe	NNP	B-NP	O
325	325	CD	I-NP	O
PO	PO	NNP	I-NP	O
TID	TID	NNP	I-NP	O
,	,	,	O	O
ECASA	ECASA	NNP	B-NP	O
325	325	CD	I-NP	O
PO	PO	NNP	I-NP	O
QDay	QDay	NNP	I-NP	O
ADDITIONAL	ADDITIONAL	NNP	I-NP	O
COMMENTS	COMMENTS	NNS	I-NP	O
:	:	:	O	O
DISCHARGE	DISCHARGE	NN	B-NP	O
CONDITION	CONDITION	NN	I-NP	O
:	:	:	O	O
Satisfactory	Satisfactory	JJ	B-ADJP	O
TO	TO	TO	B-VP	O
DO/PLAN	DO/PLAN	NN	I-VP	O
:	:	:	O	O
-LSB-	-LSB-	NNP	B-NP	O
X	X	NNP	I-NP	O
-RSB-	-RSB-	NNP	I-NP	O
Follow	Follow	NNP	I-NP	O
up	up	RB	B-ADVP	O
lumbar	lumbar	VBP	B-VP	O
MRI	MRI	NN	B-NP	O
results	result	NNS	I-NP	O
for	for	IN	B-PP	O
question	question	NN	B-NP	O
of	of	IN	B-PP	O
spinal	spinal	JJ	B-NP	O
stenosis	stenosis	NN	I-NP	O
.	.	.	O	O

-LSB-	-LSB-	NNP	B-NP	O
-RSB-	-RSB-	NNP	I-NP	O
Follow	Follow	NNP	I-NP	O
up	up	RP	B-PRT	O
A1c	A1c	NN	B-NP	B-protein
with	with	IN	B-PP	O
Lantus	Lantus	NNP	B-NP	O
and	and	CC	O	O
have	have	VBP	B-VP	O
glucose	glucose	NN	B-NP	O
monitoring	monitoring	NN	I-NP	O
diary	diary	NN	I-NP	O
.	.	.	O	O

-LSB-	-LSB-	NNP	B-NP	O
-RSB-	-RSB-	NNP	I-NP	O
Carotid	Carotid	NNP	I-NP	O
Dopplers	Dopplers	NNP	I-NP	O
in	in	IN	B-PP	O
1	1	CD	B-NP	O
months	month	NNS	I-NP	O
time	time	NN	B-NP	O
No	No	DT	B-NP	O
dictated	dictated	JJ	I-NP	O
summary	summary	NN	I-NP	O
ENTERED	ENTERED	NNP	I-NP	O
BY	BY	NNP	I-NP	O
:	:	:	O	O
MCCANDLESS	MCCANDLESS	NNP	B-NP	O
,	,	,	O	O
WAYNE	WAYNE	NNP	B-NP	O
C.	C.	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
-LRB-	-LRB-	NNP	I-NP	O
PN70	PN70	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
5/18/06	5/18/06	CD	I-NP	O
@	@	NN	I-NP	O
09	09	CD	I-NP	O
:	:	:	O	O
32	32	CD	B-NP	O
AM	AM	NN	I-NP	O
******	******	SYM	B-NP	O
END	END	NN	I-NP	O
OF	OF	IN	B-PP	O
DISCHARGE	DISCHARGE	NN	B-NP	O
ORDERS	ORDERS	NNS	I-NP	O
******	******	SYM	B-NP	O

